Estrella Immunopharma, Inc. (ESLAW)
ESLAW Stock Price Chart
Explore Estrella Immunopharma, Inc. interactive price chart. Choose custom timeframes to analyze ESLAW price movements and trends.
ESLAW Company Profile
Discover essential business fundamentals and corporate details for Estrella Immunopharma, Inc. (ESLAW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
—
Website
https://www.estrellabio.comCEO
Cheng Liu
Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
ESLAW Financial Timeline
Browse a chronological timeline of Estrella Immunopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 12 Aug 2025
EPS came in at -$0.15 falling short of the estimated -$0.07 by -119.03%.
Earnings released on 14 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%.
Earnings released on 14 Nov 2024
EPS came in at -$0.12 .
ESLAW Stock Performance
Access detailed ESLAW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.